TYK’s EGFR Inhibitor Bests Tagrisso In NSCLC Brain Metastases

Top-Line iORR Findings Released

 
• By Dexter Jie Yan
  
TYK Medicines is developing a novel EGFR inibitor for certain non-small cell lung cancer patients with brain metastases. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Focus On Asia